We spoke to Prof Anthony Harnden, the deputy chair of the Joint Committee on Vaccination and Immunisation, who says that the UK’s immunisation targets should still be within reach, despite the decision to offer under 30s alternatives to the Oxford AstraZeneca vaccine.